All In Biotech

Drug Trial Radar · NCT04289285

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

Safety and Efficacy of IBI306 in Chinese Non-familial Hypercholesterolemia Subjects at Very High or High Cardiovascular Risk: a Randomized, Double-blind and Placebo-controlled Phase III Study

Last checked: Nov 19, 2026Latest source record: Apr 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 804 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

804

Actual

Start

Apr 29, 2020

Primary completion

Feb 9, 2022

Study completion Feb 9, 2022

Sponsor

Sponsor type
Industry
First posted
Feb 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol(LDL-C) uptake. This study is being done to investigate the effects of IBI306 in Chinese people with non-familial hypercholesterolemia with very high or high cardiovascular risk. This study will see if IBI306 will reduce low density lipoprotein cholesterol (LDL-C) in Chinese people who are taking a certain type of lipid-lowering medication (statins with or without ezetimibe) and whether it causes any side effects

Conditions

  • Hypercholesterolemia

Interventions

  • IBI306 450mg SC Q4WDrug

    Subjects will receive IBI306 450mg every 4 weeks subcutaneously.

  • Placebo SC Q4WDrug

    Subjects will receive placebo every 4 weeks subcutaneously.

  • IBI306 600mg SC Q6WDrug

    Subjects will receive IBI306 600mg every 6 weeks subcutaneously.

  • Placebo SC Q6WOther

    Subjects will receive placebo every 6 weeks subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at week 48Time frame: Week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.